• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    44.01 -0.55 (-1.23%)
    Official Closing Price Updated: 6:30 PM EDT, Sep 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,575,649
    Open 44.60
    Bid (Size) 44.06 (100)
    Ask (Size) 44.08 (300)
    Prev. Close 44.56
    Today's Range 44.01 - 44.82
    52wk Range 35.12 - 64.16
    Shares Outstanding N/A
    Dividend Yield 5.79%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
    AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
    Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
    Via The Motley Fool

    Performance

    YTD
    -16.0%
    -16.0%
    1 Month
    -7.8%
    -7.8%
    3 Month
    +2.8%
    +2.8%
    6 Month
    +13.3%
    +13.3%
    1 Year
    -19.0%
    -19.0%

    More News

    Read More
    News headline image
    Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
    Via The Motley Fool
    News headline image
    Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 of the Best Growth Stocks to Buy for Less Than $100 Right Now ↗
    Via The Motley Fool
    News headline image
    Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
    Via The Motley Fool
    News headline image
    Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
    Via The Motley Fool
    News headline image
    2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
    Via The Motley Fool
    News headline image
    Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗
    Via The Motley Fool
    News headline image
    Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
    Via The Motley Fool
    News headline image
    Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
    Via The Motley Fool
    News headline image
    2 Biotech Stocks Shaping Up for Major Breakouts ↗
    Via MarketBeat
    Topics ETFs
    News headline image
    A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
    From Equity Insider
    Via GlobeNewswire
    News headline image
    3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
    Via The Motley Fool
    News headline image
    GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
    Via The Motley Fool
    News headline image
    Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗
    Via The Motley Fool
    News headline image
    Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗
    Via The Motley Fool
    News headline image
    Hims & Hers’ Revenue Beat Came With a Profitability Problem ↗
    Via MarketBeat
    Topics Earnings Lawsuit
    News headline image
    Novo Nordisk Stock: Buy or Sell? ↗
    Via The Motley Fool
    News headline image
    Better Buy: Eli Lilly vs. Novo Nordisk ↗
    Via The Motley Fool
    News headline image
    Why Eli Lilly Topped the Market Today ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk A/S Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 44.01
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 09/10/26 06:30 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.